For the quarter ending 2026-03-31, DMIIU has $509,725,411 in assets. $18,166,285 in debts.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Cash | - | 223 | 315,087 | |
| Due from sponsor-Sponsor | - | - | 566,269 | |
| Cash | 347,720 | - | - | |
| Prepaid expenses | 4,041 | 25,814 | 15,000 | |
| Total current assets | 351,761 | 26,037 | 896,356 | |
| Cash and investments held in trust account | 509,373,650 | 504,933,800 | 500,109,355 | |
| Total non-current assets | 509,373,650 | 504,933,800 | - | |
| Total assets | 509,725,411 | 504,959,837 | 501,005,711 | |
| Accounts payable | 49,166 | 99,359 | 4,592 | |
| Accrued expenses | 53,957 | 88,343 | 5,843 | |
| Accrued offering costs | 113,162 | 113,162 | 113,162 | |
| Over-allotment liability | - | - | 553,748 | |
| Promissory notes | 450,000 | - | - | |
| Total current liabilities | 666,285 | 300,864 | 677,345 | |
| Deferred underwriting fee payable | 17,500,000 | 17,500,000 | 17,500,000 | |
| Total non-current liabilities | 17,500,000 | 17,500,000 | - | |
| Total liabilities | 18,166,285 | 17,800,864 | 18,177,345 | |
| Ordinary shares subject to possible redemption, 50,000,000 shares at redemption value of 10.19 and 10.10 per share as of march 31, 2026 and december 31, 2025, respectively | 509,373,650 | 504,933,800 | 500,109,355 | |
| Ordinary shares, 0.0001 par value 220,000,000 shares authorized 13,700,000 shares issued and outstanding, excluding 50,000,000 shares subject to redemption as of march 31, 2026 and december 31, 2025 | 1,369 | 1,369 | 1,557 | |
| Accumulated deficit | -17,815,893 | -17,776,196 | -17,282,546 | |
| Total shareholders deficit | -17,814,524 | -17,774,827 | -17,280,989 | |
| Total liabilities, ordinary shares subject to possible redemption, and shareholders deficit | 509,725,411 | 504,959,837 | 501,005,711 | |
Drugs Made In America Acquisition II Corp. (DMIIU)
Drugs Made In America Acquisition II Corp. (DMIIU)